Shenzhen Glory Medical Co (002551) Fair Value & Analysis
Healthcare · CN · Market cap 2.4B CNY
Fair value as of: Jul 22, 2026
From 12 valuation models · updated 19 days ago
Share price +10.1% over the past month.
Below-average quality, and screening another 76% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥0.9100). The favourable scenario is already priced in.
- Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥2.20 – ¥6.55 · fair‑value band ¥0.6400 – ¥0.9100 · the ¥3.17 price screens above the ¥0.7600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Shenzhen Glory Medical Co (002551) currently trades at ¥3.17, while our model-based Fair Value estimate is ¥0.7600, implying the stock looks roughly 76.0% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Shenzhen Glory Medical Co generated revenue of 1.1B CNY at a net margin of -14.7%. Revenue declined 8.0% year over year. It earns a return on equity of -6.1%. The balance sheet holds a net cash position of 459M CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥0.6400 (bear case) to ¥0.9100 (bull case); at ¥3.17, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at -76%, 002551 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 12 models by family
Widest divergence: Asset-Based (¥1.97) versus Dividend Discount (¥0.2800). Highest evidence: Growth DCF (80).
Notify me when 002551 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shenzhen Glory Medical Co.,Ltd. offers hospital construction and medical system integrated solutions in China and internationally. It operates through Medical Products, Medical Services, and Health Industry segments.
Full company description
Shenzhen Glory Medical Co.,Ltd. offers hospital construction and medical system integrated solutions in China and internationally. It operates through Medical Products, Medical Services, and Health Industry segments. The company is involved in the planning, design, management, and implementation of hospital construction projects; installation of medical professional engineering projects; and medical software development activities. It also sells medical information solutions comprising digital operating rooms, surgical teaching systems, remote surgical consultation, mobile digital video station, central management platforms, and digital pre-hospital emergency platforms. In addition, the company provides medical protective equipment, including non-woven medical surgical gown and bag, medical disposable protective clothing, and disposable isolation gowns, as well as medical disposable masks; and medical consumables. Further, the company provides professional hospital digital solutions; medical services; hospital overall design and consulting services; and hospital and logistics management services. The company invests in and operates health industry parks, business incubation, and cultivation. Shenzhen Glory Medical Co.,Ltd. was founded in 1998 and is based in Shenzhen, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shenzhen Glory Medical Co reported revenue of ¥1.1B in FY2025 versus ¥1.8B in FY2021, a compound −11.9%/yr. Reported net income was −¥140M in FY2025.
002551 screens 76% overvalued. Compare with McKesson Corporation →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare Shenzhen Glory Medical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shenzhen Glory Medical Co (002551) overvalued or undervalued?
What is the fair value of 002551?
What is the quality score of 002551?
What is the revenue of Shenzhen Glory Medical Co (002551)?
What is the net profit margin of 002551?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shenzhen Glory Medical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.